Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
(Q33392920)
scientific article published on November 18, 2010
scientific article published on November 18, 2010
Language: